Table 1

Baseline demographic and clinical characteristics

Group 1: ibrutinib → ofatumumab (N = 27)Group 2: ibrutinib/ofatumumab (N = 20)Group 3: ofatumumab → ibrutinib (N = 24)All patients (N = 71)
Median age (range), years66 (51-85)63 (48-75)63 (50-71)64 (48-85)
 ≥65 years14 (52)8 (40)9 (38)31 (44)
 ≥70 years12 (44)4 (20)1 (4)17 (24)
Diagnosis, n (%)
 CLL22 (82)19 (95)24 (100)65 (92)
 SLL1 (4)0 (0)0 (0)1 (1)
 PLL1 (4)1 (5)0 (0)2 (3)
 Richter’s transformation3 (11)0 (0)0 (0)3 (4)
ECOG performance status, n (%)
 010 (37)8 (40)5 (21)23 (32)
 116 (59)11 (55)15 (63)42 (59)
 21 (4)1 (5)4 (17)6 (9)
Bulky disease, n (%)
 Lymph nodes ≥5 cm19 (70)13 (65)21 (88)53 (75)
 Lymph nodes ≥10 cm3 (11)3 (15)5 (21)11 (16)
Rai risk classification,* n (%)
 Low risk1 (4)0 (0)1 (4)2 (3)
 Intermediate risk11 (41)5 (25)8 (33)24 (34)
 High risk14 (52)14 (70)15 (63)43 (61)
 Not reported1 (4)1 (5)(0)2 (3)
Cytopenia at baseline, n (%)
 ANC ≤1500/µL5 (19)6 (30)9 (38)20 (28)
 Hemoglobin ≤11 g/dL11 (41)12 (60)10 (42)33 (47)
 Platelets ≤100 000/µL13 (48)12 (60)11 (46)36 (51)
Prognostic factors, n (%)
 Unmutated IGHV20 (74)13 (65)17 (71)50 (70)
 Del17(17)(p13.1)10 (37)9 (45)12 (50)31 (44)
 Del(11)(q22.3)9 (33)6 (30)7 (29)22 (31)
 β2-Microglobulin >3 mg/L15 (56)12 (60)13 (54)40 (56)
  • ECOG, Eastern Cooperative Oncology Group.

  • * Low risk, stage 0; intermediate risk, stage I or II; high risk, stage III or IV.